Coherus BioSciences Files 8-K with Material Agreement

Ticker: CHRS · Form: 8-K · Filed: Apr 1, 2025 · CIK: 1512762

Sentiment: neutral

Topics: material-agreement, filing

TL;DR

Coherus BioSciences signed a big deal on 3/31, check the 8-K for details.

AI Summary

On March 31, 2025, Coherus BioSciences, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The filing details include the company's principal executive offices located at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.

Why It Matters

This 8-K filing indicates a significant new agreement for Coherus BioSciences, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Coherus BioSciences?

The filing states that Coherus BioSciences, Inc. entered into a material definitive agreement on March 31, 2025, but the specific details of this agreement are not provided in the provided text.

What are the principal executive offices of Coherus BioSciences, Inc.?

The principal executive offices of Coherus BioSciences, Inc. are located at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on March 31, 2025.

What is the SIC code for Coherus BioSciences, Inc.?

The Standard Industrial Classification (SIC) code for Coherus BioSciences, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

What was the former name of Coherus BioSciences, Inc.?

The former name of Coherus BioSciences, Inc. was BioGenerics, Inc., with a date of name change on February 10, 2011.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 1, 2025 regarding Coherus BioSciences, Inc. (CHRS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing